CLINICAL DATA

Clinical Data

  1. Fluorescence-guided sampling identifies moderate-to-heavy levels of potentially harmful bacteria where standard of care does not¹.
  2. Fluorescence-guided sampling provides clinicians with more accurate swabbing results than the current gold standard, therefore finding potentially harmful bacteria before the wound becomes infected².
  3. Fluorescence-guided treatment increases the rate of wound closure in a statistically significant manner compared with the control (non-guided) period².
  4. Fluorescence-guided imaging identified moderate-to-heavy levels of Methicillin Resistant Staphylococcus Aureus (MRSA) where standard of care did not¹.
  5. Fluorescence imaging detects wound subsurface heavy bacterial load and subclinical local infection in asymptomatic patients³.
  6. Fluorescence-guided imaging differentiates P.Aeruginosa from other pathogenic bacteria².

  7. References -

    1 DaCosta RS et al; Unpublished data from on-going clinical trial at Judy Dan Research & Treatment Center, Toronto, ON (ClinicalTrials.Gov NCT01651845).
    2 Wu CY et al; Handheld fluorescence imaging device detects subclinical wound infection in an asymptomatic patient with chronic diabetic foot ulcer: a case report. International Wound Journal, April 2015.
    3 DaCosta RS et al; Point-of-care autofluorescence imaging for real-time sampling and treatment guidance of bioburden in chronic wounds: first-in-human results. PLOS one, February 2015.

Clinical Data Graphs